| Budget Amount *help |
¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
Fiscal Year 2020: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
|
|---|
| Outline of Final Research Achievements |
OGFRL1 has been identified by this principal investigator as a novel exosome-contained protein that accelerates regeneration of fibrotic liver. Through experiments using murine and human specimens, we reveled dynamic changes in production and secretion of OGFRL1 during liver injury/fibrosis and regeneration after partial hepatectomy, and validated its clinical usefulness as a marker of repair and regeneration of the injured liver. In addition, administration of genetically engineered OGFRL1-containing exosome into mice with liver fibrosis dramatically improved the survival after partial hepatectomy, indicating its therapeutic application to manage patients with advanced liver fibrosis/cirrhosis.
|
